Navigation Links
Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
Date:8/14/2008

XI'AN, China, Aug. 14 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio- Pharmaceutical Technology, Inc (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, is pleased to announce record sales and earnings for the three and six month periods ended June 30, 2008.

"In the first half of 2008, sales of our products increased substantially. Revenue received in the past six months total over $5 Million, thus representing an increase of 78 percent versus the same period in 2007," stated Jing' An Wang, CEO, Huifeng. "As such, our Gross Profit increased 88 percent to $1,839,127."

According to Mr. Wang, these figures represent record levels for HFGB. Mr. Wang further stated that Net Income was strong at four cents per share, despite being negatively impacted by expenses related to the company's recent financing activity.

"Our company continues to execute according to our strategic growth plan and there is no change to our earnings guidance of $4 million in net income for 2008," said Mr. Wang.

Gross margins for Huifeng remained strong at 34%, slightly higher than last year's 32%. Strength in the Company's main product lines of Rutin, Diosmin, and L-Rhamnose drove sales.

In Q2 2008 alone, total sales were in excess of $2.7 Million, thus representing a 10 percent sequential increase over the first quarter and a record for any quarter in company history.

Year to date, Huifeng has achieved many significant milestones:

-- Gross sales of over $5 Million; the most in any six month period of the

company's history;

-- Completed preparation for COS application and approval, including

reconfiguring of production lines and successful consultant review;

-- Boosting of Diosmin inventory ahead of deliveries to Safic-Alcan

anticipated to begin commencing in Q3 2008;

-- Significant new supplier agreement, including recently announced

contract with US-based DNP International.

"While we are certainly pleased with the 2008 year to date results, we are even more excited about the next six months," said Mr. Wang. "During the Q3 2008, Huifeng anticipates completing several key milestones including, achieving COS approval, making initial sales of Diosmin to Safic-Alcan under the stated sales agreement, as well as executing on our stated acquisition strategy."

"We are entering a very exciting phase of Huizenga's corporate development and are looking forward to demonstrating the strength of our quality platform and products throughout the remainder of FY 2008."

About Huifeng Bio-Pharmaceutical Technology, Inc. (HFGB)

Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. http://www.hfgb.cn/

For more information, please contact:

Dan Carlson,

Primary Capital LLC

Email: DCarlson@PrimaryLLC.com

Kelly Black, CEO

Premier Media Services, Inc.

Tel: +1-480-649-8224


'/>"/>
SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
2. Huifeng Bio-Pharmaceutical (HFGB) to Release First Quarter 2008 Earnings Results on May 15, 2008
3. Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities
4. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification
5. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
6. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
7. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status
8. Huifeng Bio-Pharmaceutical (HFGB) to Release Second Quarter 2008 Earnings Results on August 15, 2008
9. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
10. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
11. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):